Current/ Expected Orderbook/ Pending Orders?

Vaishali Pharma has an order of at least INR 15 crores currently in the pipeline, which is already on hand. A significant export order worth INR 600 crores was received in February, but its execution is currently stuck due to advance payment and paperwork issues in the international market. The company maintains an annual growth rate target of 18%-20%, with expectations of minimal variation. Order booking for H2 FY24 is underway, and the company is monitoring progress closely, aiming for growth compared to previous years. Repeat orders and increased market expectations contribute to margin gro

Any current/future new fundraising through debt or equity?

Currently, Vaishali Pharma Limited does not require additional capital or capacity for its growth plans. The company has made arrangements to address future needs without immediate capital infusion. There is no mention of any ongoing or planned fundraising through debt or equity in the near term. However, within the next 2-3 years, the company is considering acquiring a manufacturing facility, indicating potential future capital expenditure. No specific plans or timelines for fundraising related to this acquisition or other purposes were detailed.

Any current/future capex/capital investment/strategic investment?

Vaishali Pharma is currently operating under an asset-light model and does not require immediate additional capital or capacity. Within the next 2-3 years, the company plans to acquire a manufacturing facility to enable vertical expansion. The acquisition of the manufacturing unit aligns with their strategy to meet growing demand and move beyond contract manufacturing. No significant near-term capex is planned, but inorganic growth through factory acquisition is anticipated within the 2-3 year timeframe. The company is actively involved in product registration and expanding its product pipelin

Future growth expectations in sales/revenue/volumes?

Vaishali Pharma targets INR 400-500 crores revenue in the next 3-5 years, with an annual growth rate of 18%-20%, possibly increasing slightly. They aim to maintain sustainable and improving EBITDA margins, with growth driven by formulations and nutraceutical verticals. Major focus remains on exports, especially in Africa, with plans expanding into Gulf, Latin America, Europe, and Southeast Asia. Strategic plans include acquiring a manufacturing facility within 2-3 years to support vertical integration and continued growth from the current asset-light model. Around 350 products currentl

Future growth expectations in earnings/operating earnings/profits/EPS?

Vaishali Pharma targets revenue growth of INR 400-500 crores in the next 3-5 years, with an annual growth rate of 18%-20%, potentially increasing to 25% depending on market conditions. They anticipate sustaining or improving EBITDA margins, currently around 21%-23%, driven by higher-margin formulations and brand strength. Expansion plans include acquiring a manufacturing facility within 2-3 years to support vertical integration and increased capacity. The margin is expected to increase as brand volume grows, unlike typical trading where margin pressure occurs. Profitability is projecte

IN US

Sale is live|00:00:00left today

Vaishali Pharma LtdQ3 FY24Pharmaceuticals & Biotechnology

Vaishali Pharma Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹7.98Market Cap: ₹97 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Vaishali Pharma targets INR 400-500 crores revenue in the next 3-5 years, with an annual growth rate of 18%-20%, possibly increasing slightly.
→They aim to maintain sustainable and improving EBITDA margins, with growth driven by formulations and nutraceutical verticals.
→Major focus remains on exports, especially in Africa, with plans expanding into Gulf, Latin America, Europe, and Southeast Asia.
→Strategic plans include acquiring a manufacturing facility within 2-3 years to support vertical integration and continued growth from the current asset-light model.
→Around 350 products currently registered, with 200 more in the pipeline, expected to launch over 2-3 years, supporting long-term growth.
→Large orders, such as the INR 600 crores tender, could accelerate revenue beyond base growth projections.
→Expansion strategies also involve participation in government tenders internationally, especially in African and European markets.

Margin guidance

Category 3

→Vaishali Pharma targets revenue growth of INR 400-500 crores in the next 3-5 years, with an annual growth rate of 18%-20%, potentially increasing to 25% depending on market conditions.
→They anticipate sustaining or improving EBITDA margins, currently around 21%-23%, driven by higher-margin formulations and brand strength.
→Expansion plans include acquiring a manufacturing facility within 2-3 years to support vertical integration and increased capacity.
→The margin is expected to increase as brand volume grows, unlike typical trading where margin pressure occurs.
→Profitability is projected to improve with increased repeat orders and newer product launches, including 350 products registered and 200 in the pipeline.
→EPS growth aligns with revenue and margin improvements, with recent Q2 FY24 EPS at INR 1.61 and H1 FY24 EPS at INR 3.10, expecting upward momentum.

3 more insights locked — sign up free to unlock

Fundraise plans

→Currently, Vaishali Pharma Limited does not require additional capital or capacity for its growth plans.
→The company has made arrangements to address future needs without immediate capital infusion.
→There is no mention of any ongoing or planned fundraising through debt or equity in the near term.
→However, within the next 2-3 years, the company is considering acquiring a manufacturing facility, indicating potential future capital expenditure.
→No specific plans or timelines for fundraising related to this acquisition or other purposes were detailed.

Order book

Yes

→Vaishali Pharma has an order of at least INR 15 crores currently in the pipeline, which is already on hand.
→A significant export order worth INR 600 crores was received in February, but its execution is currently stuck due to advance payment and paperwork issues in the international market.
→The company maintains an annual growth rate target of 18%-20%, with expectations of minimal variation.
→Order booking for H2 FY24 is underway, and the company is monitoring progress closely, aiming for growth compared to previous years.
→Repeat orders and increased market expectations contribute to margin growth.
→Trade receivables are in cycle and realizable as per due dates, indicating stable order execution.
→The strategic plan includes aggressive tender submissions internationally (Africa, Europe) to expand order book in coming years.

Capex plans

Yes

→Vaishali Pharma is currently operating under an asset-light model and does not require immediate additional capital or capacity.
→Within the next 2-3 years, the company plans to acquire a manufacturing facility to enable vertical expansion.
→The acquisition of the manufacturing unit aligns with their strategy to meet growing demand and move beyond contract manufacturing.
→No significant near-term capex is planned, but inorganic growth through factory acquisition is anticipated within the 2-3 year timeframe.
→The company is actively involved in product registration and expanding its product pipeline to support growth.
→The strategic tie-up with Sankalp Life Care for nutraceutical marketing serves as an ongoing partnership to boost global reach without immediate capital investment.

How does Vaishali Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Vaishali Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings